ADC development

Sterling’s dedicated bioconjugation facility, located in Deeside, Wales, can handle a variety of batch sizes to support cGMP clinical and preclinical manufacture of antibody drug conjugates (ADCs) and bioconjugates. Through our integrated global network, we are also capable of manufacturing linker payloads...

Sterling offers a range of early phase chemistry services to ensure quality, purity and efficacy at every stage in your small molecule project. These services include: Drug discovery A comprehensive service to increase the chance of success from the start. We provide close scientific collaboration and exp...

At Sterling we have extensive API Development capabilities ranging from route scouting and design, through to process optimisation and full validation support, including quality by design (QbD). As a PDMO®, science is at the core of everything that we do and underpins our approach to API Development, coupl...

Scalable small molecule API manufacturing, from grams to tons: Our flexible and tailored approach to API manufacturing enables us to support even the most specialised and complex project requirements. Our facilities in the UK, EU and US are equipped with state-of-the-art API manufacturing equipment to supp...

The new route uses a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug

The CDMO's expertise and capabilities a "perfect fit" for overcoming the challenges of manufacturing this complex molecule

By integrating its HPAPI capabilities with those at ADC Biotechnologies' Deeside facility, small molecule CDMO will be able to offer the development and manufacturing of toxin linkers